» Articles » PMID: 410787

Lipiarmycin-resistant Ribonucleic Acid Polymerase Mutants of Bacillus Subtilis

Overview
Journal J Bacteriol
Specialty Microbiology
Date 1977 Oct 1
PMID 410787
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Lipiarmycin inhibited the activity of deoxyribonucleic acid-dependent ribonucleic acid (RNA) polymerase in vitro. We showed that inhibition was due to interference by lipiarmycin with the activity of sigma-containing molecules of RNA polymerase. Transcription by core enzyme was relatively resistant to the drug, but addition of sigma led to highly drug-sensitive RNA synthesis. We isolated lipiarmycin-resistant mutants of Bacillus subtilis and characterized them genetically and biochemically. Drug-resistant mutants contained an altered RNA polymerase that was resistant to the drug in vitro. By separation and mixed reconstitution of core and sigma fractions of mutant and wild-type RNA polymerase, we showed that lipiarmycin resistance in one mutant strain was a property of the core fraction. Genetic mapping experiments indicated that at least two lpm mutants are located between loci determining rifampin resistance and streptolydigin resistance.

Citing Articles

Stabilizing Pseudouridimycin: Synthesis, RNA Polymerase Inhibitory Activity, and Antibacterial Activity of Dipeptide-Modified Analogues.

Anwar A, Cain C, Garza M, Degen D, Ebright R, Del Valle J ChemMedChem. 2023; 19(1):e202300474.

PMID: 37751316 PMC: 10843019. DOI: 10.1002/cmdc.202300474.


RNA polymerases from low G+C gram-positive bacteria.

Miller M, Oakley A, Lewis P Transcription. 2021; 12(4):92-102.

PMID: 34403307 PMC: 8632073. DOI: 10.1080/21541264.2021.1964328.


Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.

Dorst A, Berg R, Gertzen C, Schafle D, Zerbe K, Gwerder M ACS Med Chem Lett. 2020; 11(12):2414-2420.

PMID: 33329763 PMC: 7734799. DOI: 10.1021/acsmedchemlett.0c00381.


Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3).

Lin W, Das K, Degen D, Mazumder A, Duchi D, Wang D Mol Cell. 2018; 70(1):60-71.e15.

PMID: 29606590 PMC: 6205224. DOI: 10.1016/j.molcel.2018.02.026.


Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Leeds J Cold Spring Harb Perspect Med. 2016; 6(2):a025445.

PMID: 26834162 PMC: 4743069. DOI: 10.1101/cshperspect.a025445.


References
1.
Fox T, Pero J . New phage-SPO1-induced polypeptides associated with Bacillus subtilis RNA polymerase. Proc Natl Acad Sci U S A. 1974; 71(7):2761-5. PMC: 388550. DOI: 10.1073/pnas.71.7.2761. View

2.
Sonenshein A, Cami B, Brevet J, Cote R . Isolation and characterization of rifampin-resistant and streptolydigin-resistant mutants of Bacillus subtilis with altered sporulation properties. J Bacteriol. 1974; 120(1):253-65. PMC: 245758. DOI: 10.1128/jb.120.1.253-265.1974. View

3.
Clark S, Losick R, Pero J . New RNA polymerase from Bacillus subtilis infected with phage PBS2. Nature. 1974; 252(5478):21-4. DOI: 10.1038/252021a0. View

4.
Shorenstein R, Losick R . Purification and properties of the sigma subunit of ribonucleic acid polymerase from vegetative Bacillus subtilis. J Biol Chem. 1973; 248(17):6163-9. View

5.
Price A, Frabotta M . Resistance of bacteriophage PBS2 infection to rifampicin, an inhibitor of Bacillus subtilis RNA synthesis. Biochem Biophys Res Commun. 1972; 48(6):1578-85. DOI: 10.1016/0006-291x(72)90894-7. View